


**Supplementary Figure S1.** Growth inhibition curves, showing the growth inhibition with NHI-1 (a) and PGL13 (b) in malignant mesothelioma cell lines after 72 h treatment in normoxia. Results are presented as means  $\pm$  SEM; n=3.


**Supplementary Table S1.** Intracellular nucleotide concentrations in pleural (H28, H2052) and peritoneal (MESO-II, STO) mesothelioma cells after 24 h exposure to GLUT-1 (PGL13, PGL14) and LDH-A (NHI-1, NHI-2) inhibitors at their IC<sub>50</sub> concentrations.

	cell line	inhibitor	ATP	ADP	AMP	NAD <sup>+</sup>	NADH
pleural MM	H28	control	10.6 $\pm$ 0.4	0.49 $\pm$ 0.03	0.37 $\pm$ 0.02	1.9 $\pm$ 0.1	0.005 $\pm$ 0.002
		PGL13	8.00 $\pm$ 0.01 ***	0.395 $\pm$ 0.003*	0.32 $\pm$ 0.01*	1.30 $\pm$ 0.01 ****	0.027 $\pm$ 0.004 **
		PGL14	10.3 $\pm$ 0.3	0.44 $\pm$ 0.02	0.34 $\pm$ 0.01	1.73 $\pm$ 0.04	0.04 $\pm$ 0.01
		NHI-1	10.7 $\pm$ 0.1	0.54 $\pm$ 0.02	0.33 $\pm$ 0.01	1.86 $\pm$ 0.01	0.031 $\pm$ 0.003 ***
		NHI-2	4.6 $\pm$ 0.3 ****	0.93 $\pm$ 0.03 ****	0.47 $\pm$ 0.02 ***	1.11 $\pm$ 0.03 ****	0.12 $\pm$ 0.01 ****
	H2052	control	36.6 $\pm$ 1.5	1.8 $\pm$ 0.2	0.72 $\pm$ 0.02	6.5 $\pm$ 0.2	0.9 $\pm$ 0.1
		PGL13	33.2 $\pm$ 0.8	2.07 $\pm$ 0.03	0.57 $\pm$ 0.01	5.2 $\pm$ 0.1 ****	0.89 $\pm$ 0.01
		PGL14	21.3 $\pm$ 1.1 ****	3.3 $\pm$ 0.4 ***	0.7 $\pm$ 0.1	2.3 $\pm$ 0.1 ****	0.68 $\pm$ 0.02
		NHI-1	8.2 $\pm$ 0.4 ****	0.85 $\pm$ 0.04 ****	0.26 $\pm$ 0.02 ****	1.4 $\pm$ 0.1 ****	0.6 $\pm$ 0.1 *
		NHI-2	8.3 $\pm$ 1.5 ****	0.9 $\pm$ 0.1 ****	0.19 $\pm$ 0.03 ****	1.3 $\pm$ 0.2 ****	0.6 $\pm$ 0.1 *
peritoneal MM	MESO-II	control	27.8 $\pm$ 0.3	2.0 $\pm$ 0.1	0.450 $\pm$ 0.004	4.69 $\pm$ 0.02	0.32 $\pm$ 0.03
		PGL13	27.8 $\pm$ 0.9	2.1 $\pm$ 0.1	0.41 $\pm$ 0.01	4.1 $\pm$ 0.1 *	0.28 $\pm$ 0.01
		PGL14	27.9 $\pm$ 1.1	2.3 $\pm$ 0.1	0.46 $\pm$ 0.02	4.4 $\pm$ 0.2	0.31 $\pm$ 0.02
		NHI-1	25.3 $\pm$ 0.2 *	2.1 $\pm$ 0.1	0.43 $\pm$ 0.01	4.1 $\pm$ 0.1 ***	0.33 $\pm$ 0.01
		NHI-2	21.0 $\pm$ 0.6 ****	1.99 $\pm$ 0.03	0.36 $\pm$ 0.01 **	3.1 $\pm$ 0.1 ****	0.23 $\pm$ 0.01 *
	STO	control	20.0 $\pm$ 1.0	1.4 $\pm$ 0.1	0.22 $\pm$ 0.02	3.4 $\pm$ 0.3	1.3 $\pm$ 0.1
		PGL13	14.6 $\pm$ 0.6 ***	1.23 $\pm$ 0.03	0.20 $\pm$ 0.01	2.2 $\pm$ 0.1 **	1.15 $\pm$ 0.01
		PGL14	1.05 $\pm$ 0.01 ****	1.1 $\pm$ 0.2	0.6 $\pm$ 0.1 ***	1.2 $\pm$ 0.1 ****	1.3 $\pm$ 0.2
		NHI-1	16.3 $\pm$ 0.8	1.06 $\pm$ 0.02	0.182 $\pm$ 0.002	2.4 $\pm$ 0.2	1.1 $\pm$ 0.3
		NHI-2	17.7 $\pm$ 1.7	1.4 $\pm$ 0.1	0.24 $\pm$ 0.01	2.6 $\pm$ 0.3	1.38 $\pm$ 0.04

Results are presented as means  $\pm$  SEM in nmol/mg protein; n=4, statistically different compared to control; one-way ANOVA \* p<0.05; \*\* p<0.01, \*\*\* p<0.005, \*\*\*\* p<0.0001. LDH-A: lactate dehydrogenase A; GLUT-1: glucose transporter type 1; MM: malignant mesothelioma; IC<sub>50</sub>: 50% cell growth inhibition concentration; ATP: adenosine triphosphate; ADP: adenosine diphosphate; AMP: adenosine monophosphate NADH/NAD<sup>+</sup>: reduce/oxidized nicotinamide adenine dinucleotide.



**Supplementary Figure S2. Intracellular nucleotide concentrations (a, b) and nucleotide ratios (c, d) in a human microvascular endothelial cell line (HMEC-1) after 24 h exposure to GLUT-1 (PGL13, PGL14) inhibitors.** Results are presented as means  $\pm$  SEM; n=4, one-way ANOVA \*\*  $p < 0.01$ , \*\*\*  $p < 0.005$ , \*\*\*\*  $p < 0.0001$ . GLUT-1: glucose transporter type 1; ATP: adenosine triphosphate; ADP: adenosine diphosphate; AMP: adenosine monophosphate; NADH/NAD<sup>+</sup>: reduce/oxidized nicotinamide adenine dinucleotide.



**Supplementary Figure S3. Intracellular nucleotide concentrations (a, b) and nucleotide ratios (c, d) in a human microvascular endothelial cell line (HMEC-1) after 24 h incubation with LDH-A (NHI-1, NHI-2) inhibitors.** Results are presented as means  $\pm$  SEM; n=4, one-way ANOVA \*  $p < 0.05$ ; \*\*  $p < 0.01$ , \*\*\*\*  $p < 0.0001$ . LDH-A: lactate dehydrogenase A; ATP: adenosine triphosphate; ADP: adenosine diphosphate; AMP: adenosine monophosphate NADH/NAD<sup>+</sup>: reduce/oxidized nicotinamide adenine dinucleotide.